Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

BACKGROUND: Pembrolizumab plus platinum‐based chemotherapy has demonstrated improved clinical outcomes over chemotherapy alone in patients with previously untreated advanced/metastatic non–small cell lung cancer (NSCLC), regardless of tumor programmed death ligand 1 (PD‐L1) expression. This study po...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Borghaei, Hossein, Langer, Corey J., Paz‐Ares, Luis, Rodríguez‐Abreu, Delvys, Halmos, Balazs, Garassino, Marina C., Houghton, Baerin, Kurata, Takayasu, Cheng, Ying, Lin, Jianxin, Pietanza, M. Catherine, Piperdi, Bilal, Gadgeel, Shirish M.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7692929/
https://ncbi.nlm.nih.gov/pubmed/32914866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33142
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars